Repository logo
 
Publication

Biologically based strategies for overcoming in vivo barriers with functional nano‐delivery systems

2024-08Journal article Open access
Simple item page
dc.contributor.authorAhmadzadeh, Roya
dc.contributor.authorTaheri, Seyed Alireza
dc.contributor.authorMohammadi, Neda
dc.contributor.authorHjazi, Ahmed
dc.contributor.authorMenon, Soumya V.
dc.contributor.authorKadhum, Wesam R.
dc.contributor.authorKumar, Abhinav
dc.contributor.authorShakir, Maha Noori
dc.contributor.authorShayan, Farid Karkon
dc.contributor.authorShirinkami, Nahal
dc.date.accessioned2024-10-08T11:20:05Z
dc.date.available2024-10-08T11:20:05Z
dc.date.issued2024-08
dc.description.abstractNanomedicine has been developed to reduce or eliminate the side effects and toxicity upon systemic therapy of chemotherapeutic agents and to improve their therapeutic efficacy. However, the translation of non-sized or nano-encapsulated drugs is hampered by the low penetration and accumulation of engineered nanoparticles (NPs) in sites of tumors as well as their poor pharmacokinetics. This may be due to the synthetic structure of NPs and also complicated and unknown characteristics of the solid tumor microenvironment (TME). As a result, the TME is being better identified, and the interactions between NPs and the TME or human body are being discovered or predicted. These findings have led to the development of more biocompatible, intelligent, and controllable bio-based nanoformulations that could overcome current barriers and provide sufficient drug delivery to the TME, as discussed in this paper. These formulations are designed to (i) modify the surface of NPs to improve blood circulation while reducing their off-target accumulation and side effects in vivo, (ii) pass through the tumor vasculature by modulating or targeting angiogenesis, (iii) promote NPs distribution in solid tumor regions by applying biological/physical stimuli or extracellular matrix remodeling, and (iv) overcome the cell membrane barrier and other compartments of the cell by specific cell targeting to release the payload drug into the cytoplasm or nucleoplasm. We review the various in vivo barriers that limit and complicate nano-based delivery systems, and then present strategies for developing and improving these targeted therapies in future studies.eng
dc.identifier.doi10.1002/jbt.23782
dc.identifier.eissn1099-0461
dc.identifier.issn1095-6670
dc.identifier.urihttp://hdl.handle.net/10400.1/26019
dc.language.isoeng
dc.peerreviewedyes
dc.publisherWiley
dc.relation.ispartofJournal of Biochemical and Molecular Toxicology
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBiological barriers
dc.subjectCancer
dc.subjectDrug delivery
dc.subjectNanotechnology
dc.subjectTumor microenvironment
dc.titleBiologically based strategies for overcoming in vivo barriers with functional nano‐delivery systemseng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue8
oaire.citation.volume38
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
J Biochem Molecular Tox - 2024 - Ahmadzadeh - Biologically based strategies for overcoming in vivo barriers with.pdf
Size:
1.29 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FCB2-Artigos (em revistas ou actas indexadas)